Global Blood Therapeutics appoints Wendy Yarno to its Board of Directors

– USA, CA – Global Blood Therapeutics, Inc. (NASDAQ:GBT) today announced the appointment of Wendy L. Yarno to the company’s board of directors. Ms. Yarno has more than 25 years of experience in the biopharmaceutical industry, including serving as chief marketing officer at Merck & Co. Inc.

“Wendy is an accomplished biopharmaceutical executive with a proven track record in building and leading organizations, and has significant expertise in pre- and post-launch strategy and marketing of new therapies,” said Ted W. Love, M.D., president and chief executive officer of GBT. “Her extensive experience in all areas of pharmaceutical commercialization will serve us well as we continue to advance the clinical development of voxelotor, a potentially disease-modifying therapy for the treatment of sickle cell disease. We look forward to Wendy’s contributions and guidance and we welcome her to the board.”

“With the Phase 3 HOPE Study and HOPE-KIDS 1 Study of voxelotor each well under way, and top-line data from Part A of the HOPE Study expected in the first half of 2018, this is an important time for GBT,” said Ms. Yarno. “I look forward to leveraging my expertise in drug development and commercialization, regulatory strategy and market development to help GBT achieve its mission of developing and delivering innovative treatments that provide hope to underserved patient communities.”

Ms. Yarno spent 26 years at Merck & Co., Inc., where she held commercial and human resource positions of increasing seniority, most recently as chief marketing officer. In that position, she led a global organization charged with all aspects of supporting pre-and post-launch commercialization of pharmaceuticals in more than 20 therapeutic areas. She also served as general manager, Cardiovascular/Metabolic U.S. Business Unit and as Merck’s senior vice president of human resources. Earlier in her career, she was vice president of the Women’s Health Care Franchise for Johnson & Johnson’s Ortho McNeil Pharmaceutical subsidiary. Ms. Yarno has served as a member of the board of several public and private biotechnology and medical device companies, including St. Jude Medical, Medivation, ADial Pharmaceuticals, Durata Therapeutics and Plurogen Therapeutics. Currently, she is chairperson of the board of Aratana Therapeutics and a member of the boards of Alder Biopharmaceuticals, Inovio Pharmaceuticals and MyoKardia. Ms. Yarno received an M.B.A. from Temple University, Fox School of Business, and a B.S. in business administration from Portland State University.

About Voxelotor in Sickle Cell Disease

Voxelotor (previously called GBT440) is being developed as an oral, once-daily therapy for patients with SCD. Voxelotor works by increasing hemoglobin’s affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, GBT believes voxelotor blocks polymerization and the resultant sickling of red blood cells. With the potential to restore normal hemoglobin function and improve oxygen delivery, GBT believes that voxelotor may potentially modify the course of SCD. In recognition of the critical need for new SCD treatments, the U.S. Food and Drug Administration (FDA) has granted voxelotor Fast Track, Orphan Drug and Rare Pediatric Disease designations for the treatment of patients with SCD. The European Medicines Agency (EMA) has included voxelotor in its Priority Medicines (PRIME) program, and the European Commission (EC) has designated voxelotor as an orphan medicinal product for the treatment of patients with SCD.

GBT is currently evaluating voxelotor in the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study, a Phase 3 clinical study in patients age 12 and older with SCD. Additionally, voxelotor is being studied in the ongoing Phase 2a HOPE-KIDS 1 Study, an open-label, single- and multiple-dose study in pediatric patients (age 6 to 17) with SCD. HOPE-KIDS 1 is assessing the safety, tolerability, pharmacokinetics and exploratory treatment effect of voxelotor.

About GBT

GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>